New obesity drug aims to cut side effects with smarter dosing
NCT ID NCT06718998
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 27 times
Summary
This completed Phase 1 trial tested a new drug called NNC0519-0130 in 134 overweight or obese adults. The goal was to see if different ways of increasing the dose could reduce side effects. Participants received weekly or twice-weekly injections for about 24 weeks, and researchers tracked any health issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Medical University of Graz
Graz, 8010, Austria
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NNC0519-0130
What this could lead to
If successful, this could point toward a better-tolerated obesity treatment that reduces side effects during dose increases.
What could go wrong
This is an early Phase 1 trial focused on safety, not weight loss. The drug may still cause side effects or fail in later studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.